Biogen Reports Phase 3 OPERA Results for Ocrevus in Relapsing Multiple Sclerosis

Biogen today announced results from the Phase 3 OPERA I and II trials evaluating Ocrevus (ocrelizumab) versus interferon beta-1a in patients with relapsing multiple sclerosis. The trials met their primary endpoints, demonstrating significant reductions in annualized relapse rates and disability progression with Ocrevus. These results led to FDA approval of Ocrevus for relapsing MS.